CN110327379A - A kind of activation fatty acid-g protein coupled receptor access composition - Google Patents

A kind of activation fatty acid-g protein coupled receptor access composition Download PDF

Info

Publication number
CN110327379A
CN110327379A CN201910676609.3A CN201910676609A CN110327379A CN 110327379 A CN110327379 A CN 110327379A CN 201910676609 A CN201910676609 A CN 201910676609A CN 110327379 A CN110327379 A CN 110327379A
Authority
CN
China
Prior art keywords
medicinal material
extract
composition
content
polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910676609.3A
Other languages
Chinese (zh)
Inventor
萧文鸾
伊姆兰·可汗
黄国鑫
李晓盎
夏文睿
梁伟杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macao University of Science and Technology
Original Assignee
Macao University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macao University of Science and Technology filed Critical Macao University of Science and Technology
Priority to CN201910676609.3A priority Critical patent/CN110327379A/en
Publication of CN110327379A publication Critical patent/CN110327379A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A61K36/068—Cordyceps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/074—Ganoderma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/07—Basidiomycota, e.g. Cryptococcus
    • A61K36/076—Poria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)
    • A61K36/424—Gynostemma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention belongs to field of medicaments, disclose a kind of activation fatty acid-g protein coupled receptor access composition, include polysaccharide and/or saponin(e；The polysaccharide origin is selected from least one of ganoderma lucidum, Poria cocos, umbellate pore furgus, Antrodia camphorata, mushroom, agaric, cordyceps sinensis and Cordyceps militaris in the extract of medicinal material A, the medicinal material A；The saponin(e derives from the extract of medicinal material B, and the medicinal material B is selected from least one of ginseng and its processed product, Radix Notoginseng and gynostemma pentaphylla.Composition of the present invention can effectively improve the abundance that short chain fatty acids in host generate bacterium, improve short chain fatty acids, the content of g protein coupled receptor and its downstream signaling molecule agent for peroxisome proliferator activated receptor and peptide tyrosine tyrosine；The expression of histon deacetylase (HDAC) in enteron aisle is reduced simultaneously, and then provides important guarantee for maintenance host intestine health, in addition, composition of the present invention is highly-safe.

Description

A kind of activation fatty acid-g protein coupled receptor access composition
Technical field
The invention belongs to field of medicaments, and in particular to a kind of activation fatty acid-g protein coupled receptor access composition.
Background technique
There is close symbiosis between flora and host in host intestine.Studies have shown that enterobacteriaceae in recent years Group host it is immune with metabolism in terms of play an important role, one side intestinal flora can pass through the specific antigen of generation And the stabilization of host immune function is maintained, the metabolite of another aspect intestinal flora, such as vitamin K, fatty acid (fatty acid packet Include long chain fatty acids (carbon atom number is the organic aliphatic acid greater than 12), the medium chain fatty acid (organic fatty of carbon atom number 7-12 Acid) and short chain fatty acids (carbon atom number is the organic aliphatic acid of 2-6, specifically includes acetic acid, propionic acid, isobutyric acid, butyric acid, different Valeric acid, valeric acid)) etc., necessary nutritional support can be provided for host, and important work is played in the development process for delaying disease With.However unbalanced intestinal microflora is often related to many diseases, existing evidence shows self-closing disease, A Erzi The silent disease in sea, fat, diabetes or even cancer etc. are closely bound up with the intestinal microflora of disorder.Therefore, by adjusting enteron aisle The structure of flora and its level of metabolite, to intervene generation, the development process of disease, it is considered to be scientific and reasonable way Diameter has important role to maintenance body health.
Fatty acid in enteron aisle, especially short chain fatty acids are mainly fermented by intestinal flora and are generated.In body enteron aisle Interior, fatty acid (including long-chain, middle chain and short chain fatty acids) is by its corresponding receptor, i.e. g protein coupled receptor (including length Chain, middle chain and short-chain fat acid acceptor) it combines and plays a series of important biological effects.
Short chain fatty acids generate bacterium, are the general names in enteron aisle with the intestines bacterium of metabolism synthesis short chain fatty acids ability.Short chain Fatty acid generates the macromolecular substances that bacterium can not will be absorbed by host's degradation, such as polysaccharide (cellulose), polyphenol, in colon By the effect for the enzyme that intestinal flora itself is secreted, by its catabolism and short chain fatty acids are generated.Short chain fatty acids can be The epithelial cell of colon provides nutritional support, promotes the metabolism of colon epithelial cell.Currently, many studies have shown thats increase Add the level of enteral short chain fatty acids, can effectively inhibit the generation and development of inflammatory bowel disease and intestinal cancer.
In the prior art, short chain fatty acids can be improved and generate bacterium generation and Small side effects, highly-safe drug is simultaneously few, Function and effect are good and the mechanism of action is explicitly even more few.Such as although CN102743420A discloses improvement intestinal microflora Method and application, but announcement intestinal microflora not fully aware of is how to influence intestinal health, and provided use It is limited come the effect of drugs that improves intestinal microflora.
Therefore it provides a kind of new composition especially significantly improves short chain fatty acids for improving intestinal microflora The relative abundance of bacterium and the content of associated beneficial substance are generated, and knows composition to the specific effect machine for keeping intestinal health Reason is highly important.
Summary of the invention
In view of the deficiencies of the prior art, the present invention provides a kind of activation fatty acid-g protein coupled receptor access combination Object.The composition can effectively improve the quantity that fatty acid in host intestine generates bacterium, activation fatty acid-G-protein coupling by The quantity that body access, especially raising short chain fatty acids generate bacterium, improves short chain fatty acids, g protein coupled receptor, and downstream The content of signaling molecule agent for peroxisome proliferator activated receptor and peptide tyrosine tyrosine；Histone in enteron aisle is reduced simultaneously The expression of deacetylase, and then important help is provided for the intestinal health of host.
A kind of activation fatty acid-g protein coupled receptor access composition includes polysaccharide and/or saponin(e；The polysaccharide comes Derived from the extract of medicinal material A, the medicinal material A is selected from ganoderma lucidum, Poria cocos, umbellate pore furgus, Antrodia camphorata, mushroom, agaric, cordyceps sinensis and pupa worm At least one of grass.
Preferably, the saponin(e derives from the extract of medicinal material B, and the medicinal material B is selected from the processed product of ginseng and ginseng, three At least one of seven and gynostemma pentaphylla.
The processed product includes sun-dried ginseng, red ginseng, sugared ginseng.
Wherein, sun-dried ginseng is that ginseng is processed into through drying；Red ginseng is ginseng by infiltrating, cleaning, sorting, steaming, drying in the air It shines, made of drying (red ginseng includes Korean ginseng)；Sugared ginseng is ginseng after the immersion of white sugar liquid, made of dry.
Preferably, the ginseng further includes American Ginseng.
In the composition, percentage, the content of polysaccharide is 0-100%, and the content of saponin(e is 0-100%, And the content of polysaccharide and saponin(e cannot be 0 or 100% simultaneously.In the composition, the sum of polysaccharide and the Content of saponin(e are 0-100%.
Preferably, in the composition, the content of percentage, polysaccharide is 20-80%, and the content of saponin(e is 20-80%.
Preferably, content of the polysaccharide in the extract of medicinal material A, percentage are 10-100%.
Preferably, protein and/or alkaloid are also contained in the extract of the medicinal material A.The alkaloid is water-soluble Alkaloid.
Preferably, in the extract of the medicinal material A, percentage, the content of protein is 10-20%, biology The content of alkali is 0.1-1.5%.
It is further preferred that percentage, the content of protein is 15%, raw in the extract of the medicinal material A The content of alkaloids is 1%.
Preferably, content of the saponin(e in the extract of medicinal material B, percentage are 10-100%.
Preferably, flavones and/or amino acid are also contained in the extract of the medicinal material B.
Preferably, in the extract of the medicinal material B, percentage, the content of flavones is 2-5%, amino acid Content is 1-3%.
The preparation process of the extract of the medicinal material A is as follows:
(1) medicinal material A is taken, water is added, is decocted, filtering takes filtrate, is concentrated, and concentrate is made, spare；
(2) alcohol is added into concentrate made from step (1), mixture is made, stand, centrifugation takes precipitating, water is added to make to sink Form sediment dissolution, then plus alcohol, stand, centrifugation takes precipitating, dry, the extract of obtained medicinal material A.
Specifically, the preparation process of the extract of the medicinal material A is as follows:
(1) take medicinal material A, then crush, add 8-10 times of weight water (i.e. the quality of water be medicinal material A quality 8-10 Times), it decocts, filtering, gained filtrate is concentrated under reduced pressure into 1-2 times of volume of the dosage of medicinal material A, and concentrate is made, spare；
(2) alcohol is added into concentrate made from step (1), mixture is made, the volume fraction of alcohol is 60- in mixture 90%, it stands overnight, is centrifuged, collects precipitating, water is added to dissolve precipitating, ethyl alcohol is added, stand, centrifugation takes precipitating, after dry, The extract of the medicinal material A containing polysaccharide is made.
Preferably, the temperature decocted in step (1) is 80-120 DEG C, and the time of decoction is 1-2 hours.
Preferably, step (1) Chinese medicine A after crushed medicinal material A mesh number be 50-80 mesh.
Preferably, water described in step (1) and step (2) is deionized water.
Preferably, alcohol described in step (2) is ethyl alcohol, and the concentration of the ethyl alcohol is 90-99% (volume fraction)；Further Preferably, the concentration of the ethyl alcohol is 95%.
The preparation process of the extract of the medicinal material B is as follows:
(1) medicinal material B is taken, water or alcohol are added, is decocted, filtering takes filtrate, is concentrated, and concentrate is made, spare；
(2) alcohol is added into concentrate made from step (1), mixture is made, centrifugation discards precipitating, supernatant is through dense Contracting, it is dry, the extract of medicinal material B is made.
Specifically, the preparation process of the extract of the medicinal material B is as follows:
(1) take medicinal material B, then crush, add 8-10 times of weight water or alcohol (i.e. the quality of water or alcohol be medicinal material B quality 8-10 times), decoct, filtering, gained filtrate is concentrated under reduced pressure, and concentrate is made, spare；
(2) alcohol is added into concentrate made from step (1), mixture is made, the volume fraction of alcohol is 70- in mixture 80%, centrifugation discards precipitating, supernatant is concentrated under reduced pressure, and is dried under reduced pressure to get the extract of the medicinal material B containing saponin(e.
Preferably, the temperature decocted in step (1) is 80-120 DEG C, and the time of decoction is 1-2 hours.
Preferably, step (1) Chinese medicine A after crushed medicinal material A mesh number be 50-80 mesh.
Preferably, the alcohol in step (1) is ethyl alcohol, and the concentration of ethyl alcohol is 50-60% (volume fraction).
Preferably, alcohol described in step (2) is ethyl alcohol, and the concentration of the ethyl alcohol is 90-99% (volume fraction)；Further Preferably, the concentration of the ethyl alcohol is 95%.
Composition of the present invention can be applied in feed, food, health care product and drug.
Composition of the present invention promotes the fatty acid in host intestine, especially short chain fatty acids and its protein receptor After (such as g protein coupled receptor, be the general designation of a major class membrane protein receptor) combines, short chain fatty acids-G-protein is especially activated Coupled receptor access promotes the passage downstream signaling molecule, such as agent for peroxisome proliferator activated receptor (PPAR- γ) and peptide The release of tyrosine tyrosine (PYY), and then play anticancer and anti-inflammatory effect.In addition, short chain fatty acids may also suppress body The release of interior histon deacetylase (HDAC), to inhibit the generation or development of tumour.
Compared with the existing technology, beneficial effects of the present invention are as follows:
(1) polysaccharide and saponin(e contained by composition of the present invention derive from highly-safe Chinese medicine (medicinal material A and medicinal material B)；
(2) composition of the present invention can effectively improve the abundance that short chain fatty acids in host generate bacterium, improve short chain Fatty acid, g protein coupled receptor and its downstream signaling molecule agent for peroxisome proliferator activated receptor and peptide tyrosine junket ammonia The content of acid；The expression of histon deacetylase (HDAC) in enteron aisle is reduced simultaneously, and then is provided for maintenance host intestine health Important guarantee.
Detailed description of the invention
Fig. 1 is that short chain fatty acids generate the result test chart of the relative abundance of bacterium in mouse intestinal in embodiment 4；
Fig. 2 is the result test chart of the content of mice serum Short-Chain Fatty Acids in embodiment 4；
Fig. 3 is the result test chart of the content of g protein coupled receptor in mouse intestinal in embodiment 4；
Fig. 4 is that mouse intestinal endoperoxides object enzyme body multiplication agent activated receptor contains with peptide tyrosine tyrosine in embodiment 4 The result test chart of amount；
Fig. 5 is the result test chart of the content of histon deacetylase (HDAC) in mouse intestinal in embodiment 4.
Specific embodiment
In order to allow those skilled in the art that technical solution of the present invention is more clearly understood, now enumerate following embodiment into Row explanation.It should be pointed out that following embodiment to the present invention claims protection scope do not constitute a limitation effect.
Embodiment 1 (extract of the polysaccharide from ganoderma lucidum in composition is free of saponin(e in composition)
A kind of activation fatty acid-g protein coupled receptor access composition includes polysaccharide；The polysaccharide origin is in medicinal material A Extract, the medicinal material A be ganoderma lucidum.
In the composition, percentage, the content of polysaccharide is 20%.
Content of the polysaccharide in the extract of medicinal material A, percentage are 50%.
Also contain protein and alkaloid in the extract of the medicinal material A.The alkaloid is water-soluble alkaloid.
In the extract of the medicinal material A, the content of percentage, protein is 15%, and the content of alkaloid is 1%.
The preparation process of the extract of the medicinal material A is as follows:
(1) medicinal material A is taken, is then crushed, adds the water (i.e. the quality of water be medicinal material A 9 times of quality) of 9 times of weight, decocts, Filtering, gained filtrate are concentrated under reduced pressure into 2 times of volumes of the dosage of medicinal material A, and concentrate is made, spare；
(2) alcohol is added into concentrate made from step (1), mixture is made, the volume fraction of alcohol is in mixture 80%, it stands overnight, is centrifuged, collects precipitating, water is added to dissolve precipitating, ethyl alcohol is added, stand, centrifugation takes precipitating, after dry, Gained precipitating is the extract of the medicinal material A containing polysaccharide.
The temperature decocted in step (1) is 100 DEG C, and the time of decoction is 1 hour.
Step (1) Chinese medicine A after crushed medicinal material A mesh number be 50 mesh.
Alcohol described in step (2) is ethyl alcohol, and the concentration of the ethyl alcohol is 95% (volume fraction).
Polysaccharide in embodiment 1 comes from ganoderma lucidum, and referred to as ganoderma lucidum polysaccharide, i.e., composition described in embodiment 1 contains ganoderma lucidum Polysaccharide.
Embodiment 2 (extract of the saponin(e from gynostemma pentaphylla in composition is free of polysaccharide in composition)
A kind of activation fatty acid-g protein coupled receptor access composition includes saponin(e；The saponin(e derives from medicinal material B Extract, the medicinal material B be gynostemma pentaphylla.
In the composition, percentage, the content of saponin(e is 50%.
Content of the saponin(e in the extract of medicinal material B, percentage are 70%.
In the extract of the medicinal material B, percentage, the content of flavones is 3%, and the content of amino acid is 2%.
The preparation process of the extract of the medicinal material B is as follows:
(1) medicinal material B is taken, is then crushed, (i.e. the quality of water or alcohol is the quality of medicinal material B to the water or alcohol for adding 10 times of weight 10 times), it decocts, filtering, gained filtrate is concentrated under reduced pressure, and concentrate is made, spare；
(2) alcohol is added into concentrate made from step (1), mixture is made, the volume fraction of alcohol is in mixture 80%, centrifugation discards precipitating, supernatant is concentrated under reduced pressure, and is dried under reduced pressure to get the extract of the medicinal material B containing saponin(e.
The temperature decocted in step (1) is 100 DEG C, and the time of decoction is 1 hour.
Step (1) Chinese medicine A after crushed medicinal material A mesh number be 50 mesh.
Alcohol in step (1) is ethyl alcohol, and the concentration of ethyl alcohol is 60% (volume fraction).
Alcohol described in step (2) is ethyl alcohol, and the concentration of the ethyl alcohol is 95% (volume fraction).
Saponin(e in embodiment 2 comes from gynostemma pentaphylla, and referred to as gypenoside, i.e., composition as described in example 2 contains Gypenoside.
Embodiment 3
A kind of activation fatty acid-g protein coupled receptor access composition includes polysaccharide and saponin(e；The polysaccharide origin In the extract of medicinal material A, the medicinal material A is ganoderma lucidum.
The saponin(e derives from the extract of medicinal material B, and the medicinal material B is gynostemma pentaphylla.
In the composition, percentage, the content of polysaccharide is 30%, and the content of saponin(e is 40%.
Content of the polysaccharide in the extract of medicinal material A, percentage are 70%.
In the extract of the medicinal material A, the content of percentage, protein is 15%, and the content of alkaloid is 0.5%.
Content of the saponin(e in the extract of medicinal material B, percentage are 50%.
In the extract of the medicinal material B, percentage, the content of flavones is 4%, and the content of amino acid is 2%.
The preparation process of the extract of the medicinal material A is as follows:
(1) take medicinal material A, then crush, add 10 times of weight deionized water (i.e. the quality of water be medicinal material A quality 10 Times), it decocts, filtering, gained filtrate is concentrated under reduced pressure into 1 times of volume of the dosage of medicinal material A, and concentrate is made, spare；
(2) alcohol is added into concentrate made from step (1), mixture is made, the volume fraction of alcohol is in mixture 90%, it stands overnight, is centrifuged, collects precipitating, deionized water is added to dissolve precipitating, ethyl alcohol is added, stand, centrifugation takes precipitating, does After dry, gained precipitating is the extract of the medicinal material A containing polysaccharide.
The temperature decocted in step (1) is 110 DEG C, and the time of decoction is 1.5 hours.
Step (1) Chinese medicine A after crushed medicinal material A mesh number be 80 mesh.
Alcohol described in step (2) is ethyl alcohol, and the concentration of the ethyl alcohol is 99% (volume fraction).
The preparation process of the extract of the medicinal material B is as follows:
(1) medicinal material B is taken, is then crushed, adds the alcohol (i.e. the quality of alcohol be medicinal material B 10 times of quality) of 10 times of weight, decocts It boils, filters, gained filtrate is concentrated under reduced pressure, and concentrate is made, spare；
(2) alcohol is added into concentrate made from step (1), mixture is made, the volume fraction of alcohol is in mixture 80%, centrifugation discards precipitating, supernatant is concentrated under reduced pressure, and is dried under reduced pressure to get the extract of the medicinal material B containing saponin(e.
The temperature decocted in step (1) is 110 DEG C, and the time of decoction is 1.5 hours.
Step (1) Chinese medicine A after crushed medicinal material A mesh number be 80 mesh.
Alcohol in step (1) is ethyl alcohol, and the concentration of ethyl alcohol is 60% (volume fraction).
Alcohol described in step (2) is ethyl alcohol, and the concentration of the ethyl alcohol is 99% (volume fraction).
Composition contains the polysaccharide from ganoderma lucidum and the saponin(e from gynostemma pentaphylla simultaneously in embodiment 3, i.e., simultaneously containing spirit Sesame polysaccharide and gypenoside.
Product measure of merit
Embodiment 4
Experiment: the composition of composition (containing ganoderma lucidum polysaccharide), the preparation of embodiment 2 prepared by detection embodiment 1 (contains gynostemma pentaphylla Saponin(e) and the composition for preparing of embodiment 1 and embodiment 2 bacterium-short chain fatty acids-are generated to short chain fatty acids when existing simultaneously The activation of g protein coupled receptor access.
Experimentation is as follows:
Using the spontaneous intestinal cancer (Apc of 6-8 week oldmin/+) mouse be research object, 3 experimental groups are set, and experimental group 1 is given The composition (containing ganoderma lucidum polysaccharide, being indicated with GLP) of the preparation of embodiment 1 is given, administered dose is the 750mg/kg (mouse of i.e. every kg weight The amount for giving GLP is 750mg)；Experimental group 2 gives the composition (containing gypenoside, being indicated with GpS) of the preparation of embodiment 2, gives The amount of giving is 300mg/kg (it is 300mg that the mouse of i.e. every kg weight, which gives the amount of GpS)；Experimental group 3 gives embodiment 1 and embodiment 2 composition (while containing ganoderma lucidum polysaccharide and stock indigo plant saponin(e, indicated with GLP+GpS), administered dose 750mg/kg+300mg/kg (it is 750mg that the mouse of i.e. every kg weight gives the amount of GLP simultaneously, and the amount of GpS is 300mg), continuous gavage 8 weeks.In experiment the 8th After week, the fecal sample about 0.2g of every mouse is collected respectively；After mouse anesthesia processing, mice serum is collected respectively, and Scrape mucous layer in mouse intestinal.Flora DNA in excrement is extracted using DNA extraction kit, and uses bis- generation of 16S rRNA PCR sequencing PCR is measured the composition of intestinal flora.Using UHPLC-TOF/MS (ultra performance liquid chromatography-flight time mass spectrum Instrument) content of propionic acid in mice serum, butyric acid, isobutyric acid, valeric acid and isovaleric acid is measured.Reagent is extracted using RNA Box extracts the RNA of mucous layer in mouse intestinal, and is examined using qRT-PCR (real-time fluorescence quantitative PCR) method to target gene It surveys.Separately 1 blank control group of setting, is indicated with Ctrl, and blank control group gives intragastric administration on mice water, administered dose 750mg/kg, His experiment condition is identical as experimental group 1-3.
Have detected relative abundance, short-chain fat acid content (SCFAs), G egg that short chain fatty acids in mouse intestinal generate bacterium White coupled receptor (GPRs), downstream signaling molecule agent for peroxisome proliferator activated receptor (PPAR- γ), peptide tyrosine junket ammonia The contents level of acid (PYY) and histon deacetylase (HDAC).
Fig. 1 is that short chain fatty acids generate the result test chart of the relative abundance of bacterium in mouse intestinal in embodiment 4.
Specifically, Fig. 1 is in embodiment 4 by the composition containing ganoderma lucidum polysaccharide, the composition containing gypenoside and general After composition containing ganoderma lucidum polysaccharide and the composition stomach-filling mouse containing gypenoside, short chain fatty acids in mouse intestinal are generated The influence of the relative abundance of bacterium.As shown in Figure 1, being compared with control group (Ctrl), using GLP, GpS and GLP+GpS couple Apcmin/+After mouse is treated, the quantity that short chain fatty acids in enteron aisle generate bacterium can effectively improve.
Fig. 2 is the result test chart of the content of mice serum Short-Chain Fatty Acids in embodiment 4.
Specifically, Fig. 2 is in embodiment 4 by the composition containing ganoderma lucidum polysaccharide, the composition containing gypenoside and general After composition containing ganoderma lucidum polysaccharide and the composition stomach-filling mouse containing gypenoside, mice serum Short-Chain Fatty Acids are contained The influence of amount.As shown in Fig. 2, being compared with control group, GLP+GpS can effectively improve Apcmin/+Fourth in mice serum The content of acid, isobutyric acid, valeric acid and isovaleric acid.Statistical data difference indicates with *, * indicate p < 0.05, * * indicate p < 0.01, * * * indicates p < 0.001.
Fig. 3 is the result test chart of the content of g protein coupled receptor in mouse intestinal in embodiment 4.
Specifically, Fig. 3 is in embodiment 4 by the composition containing ganoderma lucidum polysaccharide, the composition containing gypenoside and general After composition containing ganoderma lucidum polysaccharide and the composition stomach-filling mouse containing gypenoside, to g protein coupled receptor in mouse intestinal Content influence.As shown in figure 3, using qRT-PCR method to g protein coupled receptor GPR41, GPR43, GPR84, It after GPR109a, GPR119 and GPR120 are measured, is compared with control group, is treated using GLP, GpS and GLP+GpS Afterwards, the contents level of above-mentioned g protein coupled receptor can be improved in various degree.Statistical data difference indicates with *, * indicate p < 0.05, * * indicates that p < 0.01, * * * indicate p < 0.001.
Fig. 4 is that mouse intestinal endoperoxides object enzyme body multiplication agent activated receptor contains with peptide tyrosine tyrosine in embodiment 4 The result test chart of amount.
Specifically, Fig. 4 is in embodiment 4 by the composition containing ganoderma lucidum polysaccharide, the composition containing gypenoside and general After composition containing ganoderma lucidum polysaccharide and the composition stomach-filling mouse containing gypenoside, mouse intestinal endoperoxides object enzyme body is increased Grow the influence of agent activated receptor Yu peptide tyrosine tyrosine content.As shown in figure 4, being compared with control group, using GLP, GpS It, can be under significant raisings short chain fatty acids generation bacterium-short chain fatty acids-g protein coupled receptor access and after GLP+GpS treatment Swim signaling molecule agent for peroxisome proliferator activated receptor (PPAR- γ) content；Meanwhile GLP+GpS can significant raising peptide The content of tyrosine tyrosine (PYY).Statistical data difference indicates that * indicates that p < 0.05, * * indicate p < 0.01, * * * table with * Show p < 0.001.
Fig. 5 is the result test chart of the content of histon deacetylase (HDAC) in mouse intestinal in embodiment 4.
Specifically, Fig. 5 is in embodiment 4 by the composition containing ganoderma lucidum polysaccharide, the composition containing gypenoside and general After composition containing ganoderma lucidum polysaccharide and the composition stomach-filling mouse containing gypenoside, to DNA methylase inhibitor in mouse intestinal The influence of the content of enzyme.As shown in figure 5, be compared with control group, it, can not after GLP, GpS and GLP+GpS treatment The expression quantity of histon deacetylase (HDAC) is reduced with degree.Statistical data difference indicates with *, * indicate p < 0.05, * * indicate p < 0.01, * * * indicates p < 0.001.

Claims (10)

1. a kind of activation fatty acid-g protein coupled receptor access composition, which is characterized in that include polysaccharide and/or saponin(e； The polysaccharide origin is selected from ganoderma lucidum, Poria cocos, umbellate pore furgus, Antrodia camphorata, mushroom, agaric, winter worm in the extract of medicinal material A, the medicinal material A At least one of summer grass and Cordyceps militaris.
2. composition according to claim 1, which is characterized in that the saponin(e derives from the extract of medicinal material B, the medicine Material B is selected from least one of ginseng and processed product, Radix Notoginseng and the gynostemma pentaphylla of ginseng.
3. composition according to claim 1, which is characterized in that in the composition, percentage, polysaccharide Content is 0-100%, and the content of saponin(e is 0-100%, and the content of polysaccharide and saponin(e cannot be 0 or 100% simultaneously.
4. composition according to claim 1, which is characterized in that content of the polysaccharide in the extract of medicinal material A is pressed Percent by weight is 10-100%.
5. composition according to claim 1, which is characterized in that in the extract of the medicinal material A also containing protein and/ Or alkaloid.
6. composition according to claim 2, which is characterized in that content of the saponin(e in the extract of medicinal material B is pressed Percent by weight is 10-100%.
7. composition according to claim 2, which is characterized in that in the extract of the medicinal material B also containing flavones and/or Amino acid.
8. according to claim 1, composition described in any one of 4 or 5, which is characterized in that the system of the extract of the medicinal material A Standby process is as follows:
(1) medicinal material A is taken, water is added, is decocted, filtering takes filtrate, is concentrated, and concentrate is made, spare；
(2) alcohol is added into concentrate made from step (1), mixture is made, stand, centrifugation takes precipitating, adds water, adds Alcohol stands, takes precipitating, dry, and the extract of medicinal material A is made.
9. the composition according to any one of claim 2,6 or 7, which is characterized in that the system of the extract of the medicinal material B Standby process is as follows:
(1) medicinal material B is taken, water or alcohol are added, is decocted, filtering takes filtrate, is concentrated, and concentrate is made, spare；
(2) alcohol is added into concentrate made from step (1), mixture is made, centrifugation discards precipitating, and supernatant is concentrated, does It is dry, the extract of medicinal material B is made.
10. composition of any of claims 1-9 is preparing the application in feed and/or food and/or drug.
CN201910676609.3A 2019-07-25 2019-07-25 A kind of activation fatty acid-g protein coupled receptor access composition Pending CN110327379A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910676609.3A CN110327379A (en) 2019-07-25 2019-07-25 A kind of activation fatty acid-g protein coupled receptor access composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910676609.3A CN110327379A (en) 2019-07-25 2019-07-25 A kind of activation fatty acid-g protein coupled receptor access composition

Publications (1)

Publication Number Publication Date
CN110327379A true CN110327379A (en) 2019-10-15

Family

ID=68147415

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910676609.3A Pending CN110327379A (en) 2019-07-25 2019-07-25 A kind of activation fatty acid-g protein coupled receptor access composition

Country Status (1)

Country Link
CN (1) CN110327379A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107088200A (en) * 2017-05-15 2017-08-25 南昌大学 Black Ganoderma polysaccharide is used for the application for preparing mammal enterocyte inflammatory factor regulating drug

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107088200A (en) * 2017-05-15 2017-08-25 南昌大学 Black Ganoderma polysaccharide is used for the application for preparing mammal enterocyte inflammatory factor regulating drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIAO-ANG LI，等: "Cooperative effects of mushroom polysaccharides and herbal saponins on tumor growth and gut microenvironment in ApcMin/ + mice", 《ACCR ANUUAL MEETING》 *

Similar Documents

Publication Publication Date Title
CN107822948B (en) Composition with after-sun repair, oxidation resistance and whitening effects and preparation method thereof
AU2003236377B2 (en) Water soluble extract from plant of Solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract
Tian et al. Digestive characteristics of Hericium erinaceus polysaccharides and their positive effects on fecal microbiota of male and female volunteers during in vitro fermentation
JP2016522227A (en) Methods for obtaining plant extracts and related compositions
JP2016102111A (en) Pharmaceutical compositions considered as supplementary chemotherapy pharmaceuticals and applications thereof
CA2871478C (en) Pleuropterus multiflorus extract and dipsacus asperoides extract for stimulating the secretion of insulin-like growth factor and promoting bone structure growth, and method for preparing same
CN107551001B (en) A Chinese medicinal composition for preventing and treating alcoholic hepatic injury and its preparation method
US20050287230A1 (en) Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof
CN109771457A (en) Purposes of the russule extract in the preparation that preparation treatment and/or prevention high fat diet cause hepatic injury related disease
WO2020000828A1 (en) Gracilaria lemaneiformis polysaccharide having significant hypolipidemic activity and preparation method therefor and use thereof
Wang et al. Cichoric acid from extracted Echinacea purpurea induces the proliferation and apoptosis of peripheral blood mononuclear cells from yaks
CN114748518B (en) Oral preparation containing caffeic acid ester and breviscapine for treating intestinal cancer, and its preparation method
CN110327379A (en) A kind of activation fatty acid-g protein coupled receptor access composition
JP6116539B2 (en) Pharmaceutical composition containing polypeptide and having many effects in vivo and use thereof
CN106928376A (en) The separation method of skunk bush polysaccharide and its application
CN109771454A (en) Purposes of the birch young pilose antler extract in the preparation that preparation treatment and/or prevention high fat diet cause hepatic injury related disease
CN1243443A (en) Fresh rehmannia root extract for proliferation of bifidobactor and extraction method thereof
CN111617145B (en) Composition for improving expression of cell tight junction protein and preparation method and application thereof
CN112812127B (en) C20-diterpene alkaloid compound and preparation method and application thereof
JP7372659B2 (en) immunostimulant
Zuparova et al. Determining The Authenticity Of Immunacea Bio Tablets With Immunomodulatory Action
CN108159146A (en) A kind of Chinese medicine composition and preparation method for reducing blood lipid
CN115671219B (en) Traditional Chinese medicine composition for treating gout and preparation method and application thereof
JP7168196B2 (en) Intestinal barrier function improver
JP7372656B2 (en) Nutrient transport enhancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20191015